Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip).

Abstract

Background:

Gastric cancer (GC) is associated with a poor prognosis mostly due to peritoneal metastasis, which will develop in time during the patient's disease history. To prevent and treat peritoneal metastasis, different kinds of treatment regimens have been described.

Summary:

In this review, we addressed two main topics - prophylaxis and treatment of peritoneal metastasis in GC. Prevention should be directed towards diminishing cancer cell spillage and reducing adherence of cancer cells to the abdominal cavity. Postoperative washing of the abdomen with or without chemotherapy and additional heat are herein discussed.

Key Messages:

Treatment of existing peritoneal metastasis is effective in patients with limited disease and tumour spread. Cytoreductive surgery including resection of peritoneal metastasis followed directly with hyperthermic intraperitoneal chemotherapy can increase overall survival and progression-free survival in selected patients. Drugs, duration and time schedules of intraperitoneal chemotherapy are reviewed and presented. Intraperitoneal chemotherapy seems to improve the prognosis of patients with GC and peritoneal metastasis after complete resection of both primary and metastatic tumours.

• Authors: Beate Rau, Linda Feldbrügge, Felix Gronau, Miguel Enrique Alberto Vilchez, Peter Thuss-Patience, Pierre Emmanuel Bonnot, Olivier Glehen
• Journal: Visceral medicine (Visc Med) Vol. 38 Issue 2 Pg. 81-89 (Apr 2022) ISSN: 2297-4725 [Print] Switzerland
• PMID: 35614895 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022 by S. Karger AG, Basel.